In chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively
inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent …

Purpose: Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL
fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia …

Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase,
suppressing the Philadelphia chromosome-positive clone in chronic myelogenous leukemia …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Fifty patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous leukemia
(CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median …

Purpose: Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown
encouraging activity in chronic myelogenous leukemia (CML). Experimental Design: We …

Imatinib mesylate is a major advance in the therapy of patients with chronic myelogenous
leukemia (CML). Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine …

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the
balanced reciprocal translocation t (9: 22). The resulting fusion gene, the BCR-ABL, is …

Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the
development and progression of Philadelphia chromosome–positive (Ph+) chronic …

We investigated whether increasing the dose of imatinib mesylate might overcome drug
resistance in patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous …